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Abstract. Investigating the regulation of very late an­
tigen (VLA)-mediated functions, we found that TS2/
16, a mAb directed against the 0 chain of the VLA 
group of integrins, can induce binding of resting pe­
ripheral blood lymphocytes, cloned T lymphocytes, 
and Epstein Barr virus-transformed B cells to extra­
cellular matrix components, fibronectin, laminin, and 
collagen, but not to fibrinogen. The antibody stimu­
lates VLA-4-, VLA-5-, and VLA-6-mediated binding. 
Furthermore, it induces VLA-4-mediated binding to 
vascular cell adhesion molecule-1 expressed by iTNF- 
ce-stimulated endothelial cells, but it does not stimu­
late homotypic aggregation of cells as described for a 
number of anti-VLA-4o: antibodies (Bednarczyk,
J. L., and B. W. McIntyre. 1990. J. Immunol. 144: 
777-784; Campanero, M. R., R. Pulido, M. A.
Ursa, M. Rodríguez-Moya, M. O. de Landázuri, and 
F. Sánchez-Madrid. 1990. J. Cell BioL 110:2157-
2165). Therefore, the stimulating activity of this anti-01 
antibody clearly contrasts with that of the anti-VLA-4a 
antibodies, which induce homotypic cell aggregation, 
but not binding of cells to extracellular matrix compo­
nents or endothelial cells, indicating that TS2/16 may 
generate different signals.
The observation that also F(ab') 2  or Fab fragments 
of this anti-01 antibody stimulate binding to extracel­
lular matrix components and endothelial cells excludes 
the possibility that binding requires receptor crosslink­
ing, or is Fc receptor mediated. Induction of this ad­
hesion is cation and energy dependent and requires an 
intact cytoskeleton. Although changes in the confor­
mation of VLA integrins induced by this antibody may 
regulate their functional activity, the dependence on 
metabolic energy indicates that intracellular processes 
may also play a role.
T h e  very late antigens (VLAs)1 are expressed on both 
hematopoietic and nonhematopoietic cells and form 
the 01 group of the integrin superfamily of adhesion 
receptors (Hynes, 1987). Other groups of this still expand­
ing family comprise the 02, or leukocyte integrin group 
(Sanchez-Madrid et al., 1983), and the 03 group, which con­
sists of the platelet antigen Ilb/IIIa (Phillips et al., 1988) and 
the vitronectin receptor (Pytela et al., 1985). The VLA 
molecules mediate adhesion of cells with components of the 
extracellular matrix (ECM) (Hemler, 1990). Recently, it has 
been observed that VLA-4 is also able to interact with glyco­
proteins expressed at the surface of various types of cells in­
cluding endothelium. One of these ligands has been identi­
fied as the vascular cellular adhesion molecule-1 (VCAM-l) 
(Elices et al., 1990; Taichman et al., 1991).
Cornelis J. M. Melief s present address is Department of Immunohaematol­
ogy and Bloodbank, Academic Hospital Leiden, The Netherlands.
1. Abbreviations used in this paper. Coll, collagen type I; EBV, Epstein Barr 
virus; ECM, extracellular matrix; FG, fibrinogen; FN, fibronectin; HE, 
hydroethidine; LAD, leukocyte adhesion deficiency; LFA-1, lymphocyte 
function-associated antigen-1; LM, laminin; PBL, peripheral blood lym­
phocyte; TNF, tumor necrosis factor; VCAM-l, vascular cell adhesion 
molecule-1; VLA, very late activation antigen.
High affinity interaction of integrins with their respective 
ligands, requires activation of the integrin receptor. This has 
now been demonstrated for the 01 (Shimizu et al., 1990), 02 
(Van Kooyk etal., 1989; Dustin and Springer, 1989), and 03 
(O’Toole et al., 1990) group of this adhesion receptor family. 
Phorbol esters, such as PMA, are able to induce a high 
affinity state of the 01, 02, and 03 integrins (Patarroyo et al., 
1985; Phillips etal,, 1988; Shimizu, 1990; Springer, 1990; 
Wilkins et al., 1991). In addition, a number of more physio­
logical stimulatory pathways have been recognized to stimu­
late integrin-mediated adhesion. Among others, signals me­
diated through CD2 and CD3, which are expressed by T 
lymphocytes, can stimulate 01- and 02- mediated interac­
tions (Dustin and Springer, 1989; Van Kooyk et al., 1989; 
Nojima et al., 1990), and thrombin is able to induce adhe­
sion of platelets, through Ilb/IIIa, a 03 integrin (Ginsberg et
al., 1980).
We previously showed that an antibody directed against a 
unique epitope located on the a  chain of lymphocyte func­
tion-associated antigen-1 (LFA-1), is capable of inducing a 
high affinity state of LFA-1, a 02 integrin. Similarly, specific 
antibodies have been recognized that stimulate 03-mediated 
functions (Gulino et al., 1990). Recently, Campanero et al.
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(1990) and Bednarczyk and McIntyre (1990) observed that 
certain antibodies directed against VLA-4 a  subunit are 
capable of inducing homotypic aggregation of leukocytes 
suggesting that antibodies against VLA-4 can also induce a 
high affinity state of this receptor.
In the present study, we demonstrate that an anti-(31 anti­
body is also capable of inducing a high affinity state of VLA-4 
and stimulates VLA-4-mediated adhesion. In addition we 
show that several other VLA antigens that comprise the (31 
family can also be stimulated. Interestingly, a clear distinc­
tion can be made between the VLA-mediated functions 
stimulated by anti-VLAa antibodies and those stimulated by 
the anti-/31 antibody used in this study.
Materials and Methods
Cell Lines and Cell Culture
Peripheral blood lymphocytes (PBLs) were isolated from mononuclear cells 
by centrifugal elutriation as described previously (Figdor et al., 1984). The 
human Tetanus toxoid specific T helper clone HY 827 was described by 
Yssel et al. (1986); the cytotoxic, alloreactive T cell clone JS 136, directed 
against an HLA-DRw6 determinant by Borst et al. (1986). The LFA-i nega­
tive T cell clones, LAD 4, LAD 6.1, and LAD 6.6, were raised by limiting 
dilution of peripheral blood lymphocytes of a patient (VA) with leukocyte 
adhesion deficiency (LAD) lacking mRNA expression for the CD18 protein 
(Van Kooyk et al., 1989). T cell clones, KZ 21.1 and KZ 25.7 were estab­
lished from LFA4 positive lymphocytes. The B cell lines were established 
by Epstein Barr virus (EBV) transfection of B cells from patient VA and B 
cells from donor JS. Cloned T cells were cultured in Iscove’s medium sup­
plemented with 5% human serum and stimulated weekly with irradiated 
allogeneic peripheral blood mononuclear cells (PBMCs) and EBV-trans- 
formed B cells (JY), 0.2 /xg/ml phytohaemagglutinin, and 100 U/ml rIL-2, 
kindly provided by Eurocetus (Amsterdam, The Netherlands). EBV-trans- 
formcd B cells were maintained in Iscove’s medium containing 10 % FCS,
Antibodies
The following VLAa mAbs were used. HP1/2 and HP1/3 (anti-VLA-4, 
CD49d), (Campanero et al., 1990); B-5G10 (anti-VLA-4, CD49d) (Hemler 
et al., 1987); SAM-1 (anti-VLA-5, CD49e) (Keizer etal., 1987); andGoH3 
(anti-VLA-6, CD49f) (Sonnenberg et al., 1988) are directed against a  
subunits of the VLAs. The antibodies TS2/16 and A-1A5 (Hemler et al., 
1984), K20 (Amiot et a l., 1988), and AHB2 (Hall et al., 1989) are directed 
against the 01 subunit of the integrins (CD29). CLB-LFA-1/1 (CD18) 
(Miedema et al,, 1984), C17 (CD41) (Tetteroo et al., 1983), and 439.9B 
(CD61) (Falconi et al., 1988) are reactive with other ft subunits of the inte­
grins. The antibodies 32.2 and IV,3 are directed against FcyRI (CD64) and 
FcyRII (CD32) (Anderson et al., 1986), respectively, and antibody CLB- 
FcyR gran 1 against Fc-yRIII (CD16) (Klaassen et al., 1990). mAb 4B9 
recognizes VCAM-1 (Schwartz et al., 1990) and W6/32, which is used as 
control antibody reacts with MHC class I (Barnstable et al., 1978).
Fab and F(atf)2 fragments of TS2/16 were generated by papain and pep­
sin digestion as described by Mather et al. (1987) and checked for purity 
with an Fc-specific ELISA and by SDS-PAGE, followed by Coomassie blue 
staining. SDS-PAGE was carried out on vertical slab gels (5-15%) accord­
ing to a modification of the Laemmli procedure (Laemmli, 1970).
Cell Binding to ECM Components
For cell attachment to ECM, flat bottom 96-well microtiter plates (Costar, 
Cambridge, MA) were coated with 100 fd of 20 /¿g/ml fibronectin (FN),
20 /xg/ml laminin (LM), 40 /¿g/ml collagen type I (Coll), or 40 /xg/ml 
fibrinogen (FG), (Sigma Chemical Co., St. Louis, MO), for 16 h at4°C, 
washed, and subsequently incubated with 1% wt/vol BSA for 1 h by 37°C. 
T cell clones and EBV-transformed B cells were labeled with 31Cr for 
1.5-2 h, washed, and resuspended in Iscove's medium containing 0.25% 
wt/vol BSA. 1 x  104 radiolabeled cells were plated in triplicate (50 /¿I final 
volume), centrifuged for 1 min at 1,000 rpm and incubated for 30 min at 
37°C and 5% CO2. Unbound cells were removed by washing with PBS 
supplemented with 0.25% wt/vol BSA, 1 mM Mg2+, and 1 mM Ca2+.
Bound cells were lysed by detergent and the radioactivity of the lysate was 
counted in a gamma counter. Results were expressed as the mean percentage 
of cell binding from triplicate wells. For induction or enhancement of bind­
ing to ECM, 2 x 105 cells/ml were preincubated with 10 /¿g/ml purified 
TS2/16, or 50 nM PM A for 10 min. For antibody inhibition, 25 jul with 
1:100 dilution or 10 Mg/ml purified mAb was added to 25 /¿I cell suspension 
and preincubated for 20 min at 4°C. Sodium azide (2% wt/vol) and deoxy- 
glucose (50 mM, SERVA, Heidelberg, FRG) were added to inhibit cell me­
tabolism. Staurosporin (200 nM; Kyowa Hakko, Europe GMBH, Düssel­
dorf, FRG) was added to inhibit protein kinase C activity. Involvement of 
cytoskeleton was determined by adding Cytochalasin B (20 /uM; Sigma 
Chemical Co.). Cation dependence was determined by preincubation of 
cells with 5 mM EDTA or 5 mM EGTA for 30 min at 37 °C.
Cross-Competitive mAb Cell Binding Assay
For cross-competitive mAb cell binding assays, cells were preincubated (30 
min, 0°C) with different dilutions of unlabeled mAb in Iscove’s medium 
containing 0.25% wt/vol BSA. Then, purified TS2/16 mAb (10 /¿g/ml) la­
beled with 125I (Amersham International, Amersham, UK), as described 
by Greenwood et al. (1963), was added and incubated for another 30 min 
on ice. Unbound radioactivity was removed by washing four times and 
bound labeled antibody was counted in a gamma counter and expressed as 
the mean cpm of triplicate tests.
Immunofluorescence
Cells were incubated (30 min, 0°C) in PBS containing 1% wt/vol BSA 
(Sigma Chemical Co.), and 0.02% wt/vol sodium azide, with appropriate 
dilutions of the different mAb, followed by incubation with FITC-labeled 
goat F(ab')2 anti-mouse IgG antibody (GAM-FITC; Nordic, Tilburg, The 
Netherlands) or by FITC-labeled mouse anti-rat kappa antibody (MARK- 
FITC, Sanbio, Uden, The Netherlands) for 30 min at 0°C. The relative 
fluorescence intensity was measured on a FACScan (Becton Dickinson, 
Mountain View, CA).
Binding of Cells to Endothelium
Endothelial cells (2 X 105 cells/ml), isolated from human umbilical cord
veins and cultured two or three passages as described by Te Velde et al. 
(1987), were grown in 100 (xl RPMI/well containing 10% human serum, 
in FN-coated (2 /xg/100 /xl), flat bottom 96-well plates (Costar, Cambridge, 
MA). After 2 d of culturing, the cells were stimulated, for 24 h, with 100 
U/ml iTNF-a (supernatant of cDNA-transfected COS cells). Before initia­
tion of the adhesion experiment the wells with endothelial cells were washed 
with RPMI. T cells were labeled with 5lCr for 1.5-2 h, washed, and 
resuspended in Iscove’s medium with 0.25% wt/vol BSA, 1 X 104 radiola­
beled T cells were plated in triplicate (100 ¿il final volume), and incubated 
for 30 min at 37°C and 5% CO2. Unbound cells were removed by washing 
with PBS supplied with 0.25% wt/vol BSA, 1 mM Mg2+, and 1 mM Ca2+. 
Bound cells were lysed by detergent and the radioactivity of the cell lysate 
was counted in a gamma counter, Results were expressed as the mean per­
centage of cell binding from triplicate wells. For induction or enhancement 
of binding to ECM, cells were preincubated with 1:100 ascites dilution of 
niAb or 10 ¡xg/ml purified TS2/16 for 30 min at 4°C. For antibody inhibition 
studies, cells were preincubated (30 min, 4°C) with 1:100 ascites dilution 
or 10 ¿¿g/ml purified mAb.
Quantitative Aggregation Assay
Homotypic aggregation was quantitatively determined by double fluores­
cence (Kuijpers etal., 1990). Cells (2 X 106 cells/ml in Iscove’s medium) 
were stained with the red dye Hydroethidine (HE; Polyscience, Inc., War­
rington, PA; 40 mg/ml in JV,iV-dimethylacetonide) at concentrations of 3 
ng/ml, or with the green dye sulfofiuorescein diacetate (SFDA; Molecular 
Probes, Junction City, OR) at a concentration of 5 /xg/ml, After 1 h of incu­
bation at 37°C, cells were washed twice with Iscove’s medium with 10% 
FCS. Cells were seeded in round bottom wells (5 x 104 HE labeled and
5 x 104 SFDA labeled cells) in 100 fi 1. After 2 h of incubation at room 
temperature, cells were fixed with 0.5% wt/vol paraformaldehyde, and 
aggregation was counted in a FACScan. Double-colored aggregates were 
calculated as a percentage of the total HE colored events counted from 
duplicate wells.
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Results
Induction of (31-mediated Adhesion ofT  and 
B Lymphocytes to ECM
LFA-1 positive (JS 136) and LFA-1 negative (LAD 6.1) cloned 
T cells and LFA-1 positive (JS EBY) and LFA-1 negative 
(LAD EBV) EBV-transformed B cells were studied with re­
spect to VLA-mediated binding to ECM. Table I shows that 
the cloned T cells hardly bind to FN, LM, Coll type I, or
Table /. Induction o fT  and B Cell Adhesion to 
ECM  Components
Treated with
Adhesion*
BSA FN LM Coll(I) FG
% % % % %
Medium JS 136 <* < < < <
LAD 6.1 < < < < <
JS EBV < 10 < < <
LAD EBV < 9 < < <
PMA JS 136 < 37 8 12 <
LAD 6.1 < 19 18 26 <
JS EBV < 22 < < <
LAD EBV < 19 < < <
TS2/16 JS 136 < 36 14 17 <
anti-VLA-/3 LAD 6.1 < 31 28 31 <
JS EBV < 43 < < <
LAD EBV < 37 < < <
A-1A5 JS 136 < 19 < < <
anti-VLA-/3 LAD 6.1 < 11 < < <
JS EBV < 25 < < <
LAD EBV < 19 < < <
AIIB2 JS 136 < < < < <
anti-VLA-/3 LAD 6.1 < < < < <
JS EBV < < < < <
LAD EBV < < < < <
K20 JS 136 < < < < <
anti-VLA-j8 LAD 6.1 < < < < <
JS EBV < 14 < < <
LAD EBV < 11 < < <
HP 1/3 JS 136 < < < < <
anti-VLA-4 LAD 6.1 < < < < <
JS EBV < 14 < < <
LAD EBV < 12 < < <
HP 1/2 JS 136 < < < < <
anti-VLA-4 LAD 6.1 < < < < <
JS EBV < < < < <
LAD EBV < < < < <
B-5G10 JS 136 < < < < <
anti-VLA-4 LAD 6.1 < < < < <
JS EBV < 12 < < <
LAD EBV < 11 < < <
SAM-1 JS 136 < < < < <
anti-VLA-5 LAD 6.1 < < < < <
JS EBV < 12 < < <
LAD EBV < 13 < < <
* SD <3%
$ < = <5% adhesion.
FG, while the EBV transformed B cells showed significant 
binding to FN. We observed that, TS2/16, an anti-/Sl anti­
body, stimulated adhesion to FN, LM, and Coll but not to 
FG (Table I). To extend this observation, we tested a large 
panel of anti-jSl and anti-VLA-4 antibodies, as well as-a num­
ber of antibodies directed against other /? integrin subunits, 
for their capacity to induce binding of cloned T cells or EBV- 
transformed B cells to ECM (Table I) . None of the other 
anti-/3 or anti-a antibodies induced strong ECM binding, ex­
cept mAb AT A 5, which stimulated moderate binding of lym­
phocytes to FN. Furthermore, antibodies directed against 
other anti-jS integrin subunits did not induce ECM binding 
(not shown), which is not surprising since expression of these 
integrins is low or absent on these T and B cells (Table II). 
Treatment with the phorbol ester PMA also stimulated bind­
ing of both T cell clones and EBV-transformed B cells to FN, 
had a moderate effect on cloned T cell binding to LM and 
Coll, but did not stimulate binding of B cells to LM and Coll 
(Table I).
From these results we conclude that TS2/16 has a unique 
property to induce T and B cell binding to FN, and T cell 
binding to LM and Coll type I.
To exclude that the TS2/16 induction of adhesion to FN 
was restricted to the two T cell clones and B cell lines used, 
we tested a number of T cell clones and B cell lines with 
comparable expression of integrin molecules on the ceil sur­
face. Furthermore, resting lymphocytes were tested on their 
capacity to bind to ECM after induction with TS2/16. Only 
a low number of resting PBLs spontaneously adhered to FN 
and LM (17 and 8%, respectively). After incubation with 
TS2/16 adhesion of PBL to FN and LM was enhanced to 39 
and 35%, respectively. No significant binding was observed 
to Coll I and FG after TS2/16 inducement (data not shown). 
Table III shows that for all T cell clones, B cells, and resting 
PBL tested, adhesion to FN was induced by TS2/16 and in­
hibited by mAb HP1/2, an anti-VLA-4 antibody, and not by 
mAb against ¡32.
Intact Anti-(31 Antibodies} but also F(abf)2 and Fab 
Fragments Induce (31-mediated Adhesion
To determine whether TS2/16-induced adhesion required 
receptor crosslinking, or depended on the Fc part of the mol­
ecule, we prepared F(ab')i and Fab fragments. The purity of 
the preparations was checked with an Fc-specific ELISA (de­
tection level > 0.001% intact IgG) and by SDS-PAGE under 
nonreducing conditions (Fig. 1 A). Both assays showed no 
detectable level of IgG. The results in Fig. 1 B show that 
F(af/)2 and Fab fragments are as effective in inducing bind­
ing of cloned T cells to FN as intact IgG.
These results demonstrate that crosslinking of VLA mole­
cules is not required to induce adhesion, and that the Fc por­
tion of IgG plays no role. Moreover, the T cells used in this 
study are Fc receptor negative (Table II).
Anti~(31-stimulated Adhesion Is Mediated by 
Different VLA Molecules
The results shown in Table I suggest that TS2/16 stimulates 
binding through various VLA integrins, because adhesion 
was induced to FN, LM, and Coll. We performed blocking 
studies with different anti-ce antibodies to determine which 
adhesion molecules mediated induced adhesion by TS2/16
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Table IL Surface Expression oflntegrins on T and B Cells
mAb Antigen
Relative fluorescence intensity
HY 827 LAD 6.1 JS EBV LAD EBV PBL
GAM FITC Control 4 4 5 4 3
MARK FITC Control 4 3 4 3 5
CLB-10G11 VLA-2 10 10 6 5 4
J143 VLA-3 12 13 13 10 3
HP1/2 VLA-4 152 128 67 92 20
HP 1/3 VLA-4 145 128 63 88 19
B-5G10 VLA-4 136 113 58 84 16
SAM-1 VLA-5 7 7 8 6 6
GoH3* VLA-6 8 7 5 4 25
TS2/16 01 75 68 55 59 41
A-1A5 01 73 68 60 58 37
AIIB2* 01 70 80 45 66 51
K20 01 61 50 57 47 46
CLB-LFA-1/1 02 81 6 21 5 23
C17 03 4 4 6 5 6
439.9B 04 5 5 5 5 4
Control mAb
4B9 VCAM-1 5 4 5 5 4
32.2 FcvRI 6 5 5 4 3
IV ,3 FcyRII 4 5 5 7 4
CLB-Fc^R grani FC7RIII 3 4 5 4 3
* Rat antibody.
Fab fragments. The results in Fig. 2 show that TS2/16- 
induced binding of cloned T cells to FN was completely 
mediated by VLA-4 and VLA-5, whereas binding of resting 
PBL to FN was only partially dependent on VLA-4 and 
VLA-5 (Fig. 2, A and C). Furthermore, binding to LM of 
cloned T cells after TS2/16 induction, was partially mediated 
by VLA-6, whereas binding of resting PBL seemed to be 
completely dependent on VLA-6 (Fig. 2, B  and D ), appar­
ently due to the high expression of VLA-6 and the absence 
of VLA-3 on resting PBL (Table II). Inhibition of PMA- 
induced adhesion to ECM showed similar results (Fig. 2). 
mAb against 02, 03, or 04 integrins did not affect TS2/16-
Table III. Lymphocyte Adhésion to FNafter Induction
with TS2/16
Adhesion (%)*
TS2/16 induced
Without mAb HP1/2 mAb CLB-LFA1/1
activation (anti-VLA-4) (anti-/32)
T cell clones
LAD 4 14 38 10 39
LAD 6 .1 4 29 6 31
LAD 6.6 9 29 12 29
JS 136 3 19 7 17
HY 827 14 44 18 46
KZ 25.7 3 18 8 21
B cell lines
JY EBV 12 25 4 22
JS EBV 15 32 5 34
LAD EBV 9 25 2 26
Resting PBL 17 39 21 37
* SD <3%.
induced cell adhesion (not shown). No differences were ob­
tained between LFA-1 positive and LFA-1 negative T and B 
cells (not shown).
From these data we conclude that TS2/16 induces T and 
B cell adhesion to ECM by activation of various VLA inte­
grins.
Blocking of TS2/16 Stimulated Adhesion by 
Pretreatment with Other Anti-j31 Antibodies
We repeatedly found that other anti-01 antibodies, AIIB2 
and K20, were not capable of inducing adhesion, and that 
A-1A5 induced only moderate binding to FN (I&ble I). These 
three anti-01 antibodies could not inhibit TS2/16-induced 
adhesion when added simultaneously or after TS2/16 to the 
cells (not shown). Therefore, we tested their capacity to pre­
vent TS2/16-induced adhesion by incubating the cells with 
the antibodies before addition of TS2/16. The antibodies 
AIIB2 and A-1A5, but not K20, prevented induction of adhe­
sion of cloned T cells (Fig. 3 A) and EBV-transformed B cells 
(not shown) by TS2/16, indicating that AIIB2 and A-1A5 
recognize an epitope close to that of TS2/16. Crossblocking 
experiments (Fig, 3 B ) confirmed that AIIB2 and A-1A5 in­
deed prevented binding of 125I-labeled TS2/16. Consistent 
with reports in the literature (Hemler et al., 1984; Hall et 
al., 1989), incubation of the cells with AIIB2, but not A-1A5, 
inhibited spontaneous adhesion to ECM (Fig. 3 A).
From these data we conclude that TS2/16, A-1A5, and 
AIIB2 recognize closely located epitopes on the 01 subunit. 
However, these antibodies have entirely different effects on 
VLA-mediated adhesion.
Anti-(31- and PMA-induced Adhesion Have Similar 
Kinetics Characteristic for Integrin Molecules
Fig. 4 shows that TS2/16-induced adhesion of cloned T cells
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Figure I  (A) SDS 5-15% 
PAGE under nonreducing con­
ditions of 10 /xg of TS2/16 
IgGl (lane i) , 10 /¿g TS2/16 
F(ab')2 fragments (lane 2), 
and 10 fig TS2/16 Fab frag­
ments (lane 3). (B) Compar­
ison of purified TS2/16 IgG 
(-o-), TS2/16 F(ab')2 (-♦-), 
and TS2/16 Fab fragments 
(-■-) in their capacity to in­
duce binding of cloned T cells 
HY 827 to FN. One represen­
tative experiment out of two is 
shown.
to FN, LM, and Coll occurred more rapidly compared to 
adhesion induced by PM A. In addition, a higher percentage 
of the cells adhered to LM and Coll after incubation with 
TS2/16 in comparison with PMA. Adhesion is initiated after
5 min of incubation with TS2/16 and a maximum of adhesion 
is reached after 40 min. LFA4 positive and LFA-1 negative 
T cell clones showed the same kinetics (not shown).
Furthermore, we observed that TS2/16- and PMA-induced 
adhesion is cation and temperature dependent, and requires 
an intact cytoskeleton, since EDTA, incubation at 0°C, and 
cytochalasin B completely inhibited adhesion of LFA-1 nega­
tive cloned T cell to FN (Fig. 5) LM and Coll (not shown). 
Induction of adhesion by TS2/16 or PMA could not be in­
hibited by deoxyglucose or sodium azide, but a combination
LAD 6.1
VLA-4 (HP1/2)
VLA-5 (SAM-1)
VLA-6 (GoH3)
VLA-4 + VLA-5
PBL
VLA-4 (HP1/2)
VLA-5 (SAM-1)
Fibronectin Lamimn
VLA-6 (GoH3)
VU -4  + VLA-5
120 0
* D
H
H
120
T"20 —r~40 60 80 100 120
Inhibition of Induced adhesion (%)
Figure 2 . Inhibition of cell 
binding to FN and LM. Cells 
were stimulated with TS2/16 
(*) or PMA (m) for 10 min. 
Subsequently adhesion was 
followed for 30 min with an 
inhibitory antibody as indi­
cated . Binding of LFA-1 nega­
tive cloned T cells to FN (A), 
and LM (B), and resting PBL 
to FN (C), and LM (D). One 
representative experiment out 
of three is shown.
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Figure 6. TS2/Ì6 enhanced binding of cloned T cells to iTNF-a- 
activated cultured human endothelial cells. Adhesion was measured 
after treatment of (¿4) LAD 6.1 (LFA-1 negative) and (B) JS 136 
(LFA-1 positive) cells with medium (□), TS2/16 (■) and HP1/3 
(E3), Anti-VLA-4, anti-VCAM-1 and anti-LFA-1 antibodies were 
tested on their capacity to inhibit adhesion. One representative ex­
periment out of five is shown.
VLA-4-mediated adhesion depended on the expression of 
VCAM-1, which was best visualized with LFA-1 negative 
(LAD) cells and after treatment of the endothelial cells with 
cytokines like iTNF-a: (Fig. 6 A). TS2/16 was capable to en­
hance binding to cloned LAD T lymphocytes to iTNF-
a-treated (24 h), VCAM-1 positive endothelial cells (Fig. 6 
A) but not to untreated endothelium (not shown). TS2/16 en­
hancement of adhesion to iTNF-a-stimulated endothelium 
of LFA-1 positive cells (JS 136) was hardly possible since 
these cells utilize primarily the LFA-1/ICAM pathway (Fig.
6 B). Both anti-VCAM-1 and anti-V LA-4 antibodies inhibited 
TS2/16-induced adhesion of LFA-1 negative cloned T lym­
phocytes, demonstrating that TS2/16 specifically stimulated
■
the VLA-4/VCAM-1 adhesion pathway (Fig. 6 A), whereas 
LFA-1 positive cloned T cells (Fig. 6 B )  were inhibited by 
antibodies against the LFA-1 0 chain. However, after induc­
tion with TS2/16 the inhibitory capacity of the LFA-1 mAb 
decreased, suggesting a more dominant role for the VLA- 
4/VCAM-l adhesion route (Fig. 6 B ). Pretreatment of the 
cells with mAb AIIB2, a distinct anti-01 antibody, com­
pletely abrogated TS2/16-induced adhesion (not shown), 
comparable to the TS2/16-induced adhesion to ECM (Fig. 
3 A ), confirming that the epitope recognized by AIIB2 
prevented binding of TS2/16.
From these results we conclude that 01-induced adhesion 
via VLA-4 implicates both adhesion to FN and to VCAM-1.
TS2/16 Does Not Stimulate Homotypic 
Cell Aggregation
None of the anti~VLA a  subunit antibodies used in this study 
were capable of inducing adhesion to ECM or endothelial 
cells (Thble I, Fig. 6). Recently it has been reported that cer­
tain anti-VLA-4 antibodies were capable of inducing adhe­
sion (Campanero et al., 1990; Bednarczyk and McIntyre,
1990). These observations were confirmed by the results in 
Fig, 7, which show that mAb HP1/3 directed against VLA-4 
induced homotypic aggregation of both LFA-1 positive and 
LFA-1 negative cloned T cells and EBV-transformed B cells. 
In contrast, we never observed homotypic aggregation in-
LAD 6.1 JS 136
medium
HP1/3
TS2/16
PMA
T -
10
LAD EBV
medium
HP1/3
TS2/16
PMA
~r
20 30
JS EBV
30 0
aggregation
Figure 7. Homotypic aggrega­
tion of LFA-1 positive (JS), 
and LFA-1 negative (LAD) 
cloned T and EBV transformed 
B cells. Cells were stimulated 
with medium, HP1/3 (anti- 
VLA-4) , TS2/16 (anti-01), and 
PMA. Antibodies HP1/2, (*, 
anti-VLA-4), CLB-LFA-1/1 (®, 
anti-02) and W6/32 (□, con­
trol mAb) were tested on their 
capacity to inhibit adhesion. 
One representative experiment 
out of four is shown.
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duced by TS2/16. HP1/3-induced aggregation was inhibited 
by anti-VLA-4 antibody (HP1/2) and not by mAb against 02 
(CLB-LFA-l/i), demonstrating the specificity of the re­
sponse. Furthermore, PMA readily induced cell aggregation 
of LFA-1 positive cells, which could be inhibited by anti-02 
antibody, but hardly by blocking anti-VLA-4 antibody 
(HP1/2).
These results indicate that TS2/16 and the stimulating anti- 
VLA-4a antibodies (Campanero et al., 1990; Bednarczyk 
and McIntyre, 1990) may distinctly regulate VLA-mediated 
adhesion. PMA mimics the effects induced by both anti-a or 
-0 antibodies.
Discussion
High affinity interactions of integrins with their respective 
ligands require activation of the integrin receptor. This has 
now been demonstrated for the 01 (Nojima et aL, 1990), 02 
(Van Kooyk et ah, 1989; Dustin and Springer, 1989), and 03 
(O’Toole et al., 1990) group of this adhesion receptor family. 
PMA has been recognized to induce 02-mediated adhesion 
(Patarroyo et al., 1985; Springer, 1990), 03-mediated adhe­
sion (Phillips et al., 1988), and more recently also 01- 
mediated adhesion (Shimizu et al., 1990).
We have previously observed that 02-mediated adhesion 
can be induced by an antibody, termed NKI-L16, (Keizer et 
al., 1988) directed against a Ca2+~dependent epitope lo­
cated on the a  subunit of LFA-1 (Van Kooyk et al., 1991). 
The antibody induces homotypic lymphocyte aggregation, 
as well as binding to purified ICAM-1 (Van Kooyk et al.,
1991). In addition, the antibody enhances LFA~l-dependent 
adhesion to endothelium (our unpublished results). As ex­
pected, expression of the epitope recognized by TS2/I6 is not 
dependent on the presence of divalent cations (not shown), 
since the cation binding domains are located on the a  subunit 
of integrins. In this respect, TS2/16 contrasts with NKI-L16 
or antibody 24, both of which recognize a  subunits of the 
02 group of integrins (Dransfield and Hogg, 1989). Never­
theless, a striking parallel exists between the earlier observa­
tions with NKI-L16 and those reported with TS2/16 in this 
paper (a) Both antibodies induce adhesion to their respective 
ligands. (b) Induction of adhesion is not dependent on the Fc 
portion of the antibody, (c) Stimulation of adhesion is also 
not dependent on receptor crosslinking, since Fab fragments 
of both antibodies are as effective as IgG. (d) The kinetics 
of the induced adhesion by both antibodies parallels that of 
PMA. (e) Induction of adhesion requires an intact cytoskele- 
ton and the presence of divalent cations, all characteristics 
of integrin-mediated interactions, (f) The induction of VLA- 
mediated cell adhesion by TS2/16 is dependent on metabolic 
energy, since a combination of deoxyglucose and sodium 
azide prevents induction of adhesion. We have previously 
reported that induction of LFA-l-mediated cell adhesion is 
not affected by sodium azide (Van Kooyk et al., 1991). Simi­
larly deoxyglucose alone does not affect adhesion (our un­
published results). However, a more detailed analysis shows 
that a combination of azide and deoxyglucose is inhibitory 
(our unpublished results), similar to what we observe for 
TS2/16.
One explanation for the capacity of these antibodies to in­
duce cell adhesion is that they affect the tertiary structure of 
integrins, and that they induce a high affinity state of the
receptor by conformational changes. Gulino et al. (1990) 
elegantly demonstrated that this can indeed be the case. They 
have shown that a high affinity state of Ilb/IIIa can be induced 
by anti-IIb antibodies in isolated Ilb/IIIa molecules bound to 
a cell-free substrate (Gulino et al., 1990). Thesé results also 
demonstrate that high avidity interactions can be obtained in 
the absence of associated molecules, for instance, cytoskele- 
tal elements. Induction of 01- (this study) and 02- (Van Kooyk 
et al., 1991) mediated interactions by the antibodies TS2/16 
and NKI-L16, respectively, may also involve conformational 
changes, but their dependence on metabolic activity of the 
cell suggests that intracellular processes play a role. At pres­
ent it is not known which steps in the adhesion process are 
affected by these inhibitors of cell metabolism. It is tempting 
to speculate that direct conformational changes induced by 
these antibodies affect intracellular changes, for example the 
association of the intracellular domains of these integrin 
molecules with the cytoskeletal elements, and that these lat­
ter interactions are disturbed by metabolic inhibitors. This 
hypothesis is supported by the observation that induction of 
a high affinity state of LFA-1 induced by CD2 and CD3 trig­
gering, or PMA is completely abrogated by the protein ki­
nase inhibitor staurosporin or by azide alone, whereas this 
does not affect NKI-L16-induced adhesion (Van Kooyk et 
al.s 1991). Similarly, staurosporin inhibits PMA-induced 
adhesion (Fig. 5) but not TS2/16-induced adhesion via 01.
TS2/16 specifically induces binding to different ligands of 
VLA integrins used in this study, including extracellular ma­
trix components (FN, LM, Coll type I) and cell surface mol­
ecules (VCAM-1). It is of interest to note that, on cloned T 
cells but not on EBV-transformed B cells, expression of the 
a  subunit of VLA-4 is much higher than that of the 01 subunit 
(Table II), suggesting a possible association of the VLA a  
subunit with a 0 subunit on cloned T cells other than the ones 
we have tested, Furthermore, it is noteworthy that binding 
to LM can be readily induced despite the low expression of 
VLA-6 on the T cell clones used in this study. In addition, 
the mAb blocking studies indicate that binding of cloned T 
cells to LM is not exclusively mediated by VLA-6, suggest­
ing that other LM receptors (VLA-2 and VLA-3) are in­
volved. In contrast, binding of resting PBL to LM is com­
pletely VLA-6 dependent, according to the high expression 
of VLA-6. Binding to FN implicated both the so called CS-1 
site (Wayner et al., 1989) and the RGD site (Ruoslahti and 
Pierschbacher, 1987) since both VLA-4- and VLA-5-medi- 
ated FN binding has been observed, respectively. This sug­
gests that the activity of TS2/16 is not restricted to certain 
VLA molecules but probably involves all members of this 
integrin group. In addition, the results emphasize a major 
role for the 01 subunit in the regulation of VLA-mediated 
adhesion. Similarly, anti-03 antibodies have been demon­
strated to stimulate 03-mediated adhesion (Kouns et al., 
1990). This function is however not restricted to anti-0 anti­
bodies, since stimulatory anti-a antibodies have also been 
described (Gulino et al., 1990).
A clear distinction can be made between the stimulatory 
activities of certain antibodies against the VLA-4a subunit 
and the anti-01 antibody used in this study. Previous reports 
show that anti-VLA-4a antibodies can induce homotypic cell 
aggregation (Campanero et al., 1990; Bednarczyk and 
MacIntyre, 1990). Our present observations are in line with 
these studies and indicate that anti-VLA-4ce antibodies
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stimulate homotypic cell aggregation but are unable to in­
duce binding to isolated ECM components or to VCAM-1, 
as measured by binding to iTNF-a-stimulated endothelium. 
Similar observations have been made in a study in which a 
large panel of anti-VLA-4o! antibodies has been tested (Pu­
lido et al., 1991). In contrast to these anti-a antibodies, 
TS2/16 does not induce homotypic aggregation but stimu­
lates all other VLA-mediated interactions tested so far. Fur­
thermore, the study of Neugebauer et al. (1991) indicates that 
various VLA-mediated functions can be distinctly regulated 
through the ¡31 subunit. They have observed that an anti-/31 
antibody inhibits adhesion to vitronectin but at the same time 
stimulates adhesion to LM and Coll. From these results two 
conclusions may be drawn: (a) VLA-mediated functions can 
be differentially regulated at the cell surface, depending on 
the epitope that is triggered; and (b) VLA-mediated homo­
typic cell aggregation may require other signals than interac­
tions of VLA molecules with ECM or VCAM-1. This latter 
conclusion is supported by the observation that VLA- 
4-mediated homotypic adhesion is not mediated through 
VCAM-1 (Pulido et al., 1991). Moreover, the T and B cells 
used in this study do not express VCAM-1 (Table III).
Only a limited number of antibodies is capable of stimulat­
ing VLA integrin-mediated functions. Merely anti-a anti­
bodies directed against certain epitopes of VLA-4 induce 
aggregation (Pulido et al., 1991)5 whereas of all the antibod­
ies tested in this study, TS2/16 is the only anti-/31 antibody 
capable of inducing strong binding of cloned T lymphocytes 
and EBV-transformed B lymphocytes to ECM and VCAM-1. 
This observation suggests that TS2/16 recognizes a unique 
epitope on the 01 subunit despite the fact that other antibod­
ies, A-1A5 and AIIB2, have been allocated to the same or a 
closely related site (Fig. 3 B\ Hemler et al., 1984). Cross­
blocking and adhesion inhibition studies (Fig. 3) suggest that 
A-1A5, AIIB2, and TS2/16 recognize partially overlapping, 
but functionally different epitopes. The differences observed 
between cloned T and EBV-transformed B cells in VLA- 
mediated adhesion can be due to variable cleavage of the a-4 
molecule (Hemler et al., 1990), or to differences in glycosy- 
lation, which can directly alter the binding properties of anti­
bodies to VLA-4. Similar to these findings, induction of ¡32 
or ¡33 integrin-mediated adhesion is also limited to antibod­
ies directed against specific epitopes (Van Kooyk et al., 
1991; Gulino et al., 1990; Kouns et al.s 1990). Little is 
known about the intracellular events stimulated by TS2/16 or 
by the stimulating anti-VLA4a antibodies that induce aggre­
gation. The functional data suggest different signalling path­
ways depending on the epitope against which the antibody 
is directed. So far we can not dissect differences in signal 
transduction. PM A, which stimulates both homotypic adhe­
sion and binding to ECM or VCAM-1 and thus behaves like 
a stimulating anti-VLA-4a and anti-/? antibody, is sensitive 
to PKC inhibitors, whereas TS2/16-stimulated adhesion is 
insensitive. These findings suggest that two or three distinct 
intracellular events may be operative in VLA-4-mediated 
adhesion. Additional evidence supporting the concept that 
intracellular signals are generated by VLA integrins and 
regulate leukocyte functions, comes from observations that 
VLA-ligand interactions alone, or in conjunction with anti- 
CD3 antibodies, stimulate serine esterase release by cyto­
toxic T cells, T lymphocyte proliferation, and cytokine 
production by T helper ceils or hybridoma cells (Davis et a l.,
1990; Nojima et al., 1990; Yamada et al., 1991). Alterna­
tively, binding of antibodies against VLA-4 or j31 may dis­
tinctly affect the tertiary structure of the molecules, thus, 
resulting in different binding properties of VLA-4.
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